Literature DB >> 34599436

MiR-744 Functions as an Oncogene Through Direct Binding to c-Fos Promoter and Facilitates Non-small Cell Lung Cancer Progression.

Shangbiao Li1, Simiao Qiao1, Na Li1, Xiaoxia Zhu2.   

Abstract

Metastasis is the leading cause of death in non-small cell lung cancer (NSCLC) patients. Previously, we reported that miR-744 exerted proto-oncogenic function in nasopharyngeal carcinoma, but the role of miR-744 during NSCLC development has not been established. We focused on the function and molecular mechanism of miR-744 in NSCLC. The clinical cohort data from TCGA were analyzed for the correlation of miR-744 and outcomes in NSCLC patients. Gain- and loss-of-function experiment was performed by transfection with miR-744 agomir or antagomir in NSCLC cell lines. The expression of mRNA and protein were analyzed by qPCR assays and Western blotting respectively. Cellular proliferation, migration, and invasion were analyzed by CCK8 assays, wound healing, and transwell assays, respectively. Promoter activities and gene transcription were analyzed by luciferase reporter assays. Xenograft model was applied for in vivo study. High miR-744 expression correlated with lymph node metastasis and poor prognosis in NSCLC patient. MiR-744 aggravated the growth, invasion, and metastasis of NSCLC cells eventually induced the malignant phenotype and promotes radio/chemoresistance in vitro. The -1195 to -1227 and -298 to -323 bp upstream of c-FOS gene was observed to bind with miR-744. Lastly, miR-744 acted as a tumor promoter in lung cancer growth and metastasis in vivo. Taken together, our results indicated that miR-744 up-regulated c-Fos by binding with its promoter contributed to development of NSCLC cells malignant phenotype. Our findings highlight the potential value of miR-744, which may serve as a possible therapeutic target for NSCLC.
© 2021. Society of Surgical Oncology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34599436     DOI: 10.1245/s10434-021-10688-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

1.  MTA1 gene silencing inhibits invasion and alters the microRNA expression profile of human lung cancer cells.

Authors:  Xiaoxia Zhu; Xiao Zhang; Haofei Wang; Qingcui Song; Gong Zhang; Lei Yang; Jian Geng; Xiangzhao Li; Yawei Yuan; Longhua Chen
Journal:  Oncol Rep       Date:  2012-04-20       Impact factor: 3.906

2.  Up-regulation of serum miR-744 predicts poor prognosis in patients with nasopharyngeal carcinoma.

Authors:  Qingsong Yu; Fangrong Zhang; Zhengde Du; Yi Xiang
Journal:  Int J Clin Exp Med       Date:  2015-08-15

3.  Oncogenic miR-744 promotes prostate cancer growth through direct targeting of LKB1.

Authors:  Minglei Zhang; Hai Li; Yun Zhang; Hongyan Li
Journal:  Oncol Lett       Date:  2018-12-11       Impact factor: 2.967

4.  MicroRNA-744 promotes carcinogenesis in osteosarcoma through targeting LATS2.

Authors:  Liangzhi Sun; Ming Liu; Suxian Luan; Yulin Shi; Qiang Wang
Journal:  Oncol Lett       Date:  2019-06-26       Impact factor: 2.967

5.  miR-744-5p Inhibits Non-Small Cell Lung Cancer Proliferation and Invasion by Directly Targeting PAX2.

Authors:  Shaolin Chen; Fei Shi; Weixing Zhang; Yuqi Zhou; Jing Huang
Journal:  Technol Cancer Res Treat       Date:  2019-01-01
  5 in total
  2 in total

1.  MiRNA expression profiling in adenocarcinoma and squamous cell lung carcinoma reveals both common and specific deregulated microRNAs.

Authors:  Veronika Petkova; Dora Marinova; Silva Kyurkchiyan; Gergana Stancheva; Evgeni Mekov; Darina Kachakova-Yordanova; Yanina Slavova; Dimitar Kostadinov; Vanyo Mitev; Radka Kaneva
Journal:  Medicine (Baltimore)       Date:  2022-08-19       Impact factor: 1.817

2.  miRNA and mRNA Expression Profiles Associated with Lymph Node Metastasis and Prognosis in Penile Carcinoma.

Authors:  Claudio B Murta; Tatiane K Furuya; Alexis G M Carrasco; Miyuki Uno; Laura Sichero; Luisa L Villa; Sheila F Faraj; Rafael F Coelho; Giuliano B Guglielmetti; Mauricio D Cordeiro; Katia R M Leite; William C Nahas; Roger Chammas; José Pontes
Journal:  Int J Mol Sci       Date:  2022-06-26       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.